Emapalumab Prevention of CAR-T Cell Associated Toxicities
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Recruiting · NCT06550141 · Registry updated 2026-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Emapalumab Prevention of CAR-T Cell Associated Toxicities | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary mediastinal large B-cell lymphoma | Recruiting | Phase 2 | 2026-10-06 | NCT06550141 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Marcela V. Maus, M.D.,Ph.D. | 6 |
| Swedish Orphan Biovitrum | 21 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital | Boston | United States | 1015 |